Document is current
Any future updates will be listed below
-
Authors
Thottarath, Sridevi
Tsai, Wei-Shan https://orcid.org/0000-0001-5945-9316
Gurudas, Sarega
Pearce, Elizabeth
Chueng, Chui Ming Gemmy
Yamaguchi, Taffeta Ching Ning
Sivaprasad, Sobha https://orcid.org/0000-0001-8952-0659
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim (SIVS 1048, SIVS 1048, SIVS 1048, SIVS 1048, SIVS 1048, SIVS 1048)
- License Information
-
More Information
Article History
Received: 1 July 2024
Revised: 12 November 2024
Accepted: 19 November 2024
First Online: 27 November 2024
Competing interests
: The authors declare no competing interests. Sridevi Thottarath and Wei-Shan Tsai has received travel support from Boehringer Ingelheim. Dr. Sivaprasad reported receiving financial support from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Pharmaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics and Sanofi. Sobha Sivaprasad is the Editor-in-Chief of EYE. Dr Cheung is a consultant for Topcon, Novartis, Bayer, Allergan, Roche, Boehringher-Ingelheim, and Samsung. Dr Cheung is a member of the editorial board of EYE. Taffeta Ching Ning Yamaguchi is an employee of Boehringer-Ingelheim.
